Plain-English translation of NCT06317701 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is investigating whether hypoglossal nerve stimulation (a surgically implanted device that gently stimulates a nerve to keep your airway open during sleep) can improve your body's ability to control blood sugar and reduce your risk of heart disease. Researchers know that untreated sleep apnea increases the risk of diabetes and heart problems, and that CPAP machines can help—but many people struggle to use them consistently. This study wants to understand whether this treatment option might work even better for people who cannot tolerate CPAP.
About half of people with sleep apnea stop using CPAP machines because they find them uncomfortable or inconvenient, which means they miss out on the health benefits. While hypoglossal nerve stimulation has been approved by the FDA and shown to be safe and effective at treating sleep apnea itself, no one has studied whether it also improves the metabolic and heart health problems that come with untreated sleep apnea.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will undergo a special sleep endoscopy procedure to confirm the type of airway collapse you have. If you are eligible for the nerve stimulation implant, you will receive the surgical procedure and then complete blood tests, sleep studies, and other metabolic measurements before surgery and at follow-up visits to track how the treatment affects your blood sugar, heart health, and sleep quality. If you have a type of airway collapse that makes you ineligible for surgery, you will complete the same measurements once for comparison purposes.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States
Sponsor
University of Chicago
Enrollment target
~30 participants
Started
April 2024
Primary completion
April 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Phillip LoSavio, MD, MS
University of Chicago
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.